ReemKarmaliMD

Hematologic Oncology

Associate Professor, Division of Hematology/ Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Cancer Center

Join to view full profile

Dr. Karmali is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Karmali's full profile

Already have an account?

Office
675 N Saint Clair St
Chicago, IL 60611
Phone+1 312-695-0990

Fax+1 312-695-1106
Is this information wrong?

Summary

Dr. Reem Karmali is an oncologist in Chicago, IL and is affiliated with Northwestern Memorial Hospital. She received her medical degree from University of Western Ontario and has been in practice 11 years. She specializes in hematologic oncology.

Education & Training

Rush University Medical CenterFellowship, Hematology and Medical Oncology, 2012
Rush University Medical CenterResidency, Internal Medicine, 2009
University of Western OntarioClass of 2006

Certifications & Licensure

IL State Medical License 2006 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies Start of enrollment: 2018 Mar 29
Completed
Phase 1, Phase 2
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Start of enrollment: 2018 Nov 20
Suspended
Phase 1, Phase 2
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Start of enrollment: 2019 Mar 13
Active, not recruiting
Phase 1
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2021 Nov 12
Active, not recruiting
Phase 2
Roles: Principal Investigator
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma Start of enrollment: 2022 Mar 21
Recruiting
Phase 2
Roles: Contact, Principal Investigator
DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Recruiting
Phase 2
Roles: Contact
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2024 Apr 24
Not yet recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Michael Maris, Gilles Salles, Won Seog Kim, Tae Min Kim, Roger M Lyons, Martha Arellano, Reem Karmali, Gary Schiller, Elizabeth Cull, Camille N Abboud, Connie Batlevi,...> ;Targeted Oncology. 2024 Apr 29
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.
Karmali, R., Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo Gordon, Jane Winter, Shuo Ma, Valerie Nelson, Timothy S Fenske, Nirav N Shah, Deepa Jagadeesh, Andreas Kl...> ;Blood Advances. 2024 Apr 9
Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-cell nHL Treated with CAR-T.
Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Tamara K Moyo, Vaishalee P Kenkre, Thomas A Ollila, Lindsey A Fitzgerald, Brian T...> ;Blood Advances. 2024 Mar 26
Dosing of 7 + 3 induction chemotherapy in a patient with acute myeloid leukemia (AML) and morbid obesity.
Stephanie Franco, Talha Khan, Shira Dinner, Reem Karmali, Megan Melody> ;Journal of Oncology Pharmacy Practice. 2024 Mar 21
Subsequent Malignant Neoplasms in Patients Previously Treated with Anti-CD19 CAR T-Cell Therapy.
Megan Melody, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Pamela Blair Allen, Tamara K Moyo, Vaishalee P Kenkre, Thomas A Ollila, Lindsey A Fitzgerald, Br...> ;Blood Advances. 2024 Mar 18
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
Hill, B., Ma, S., Zent, C., Baran, A., Wallace, D., Advani, A., Winter, A., Winter, J., Gordan, L., Karmali, R., Liesveld, J., Mulford, D., Rowland, C., Bui, A., Sport...> ;Blood Advances. 2024 Jan 23
Harnessing the Systemic Biology of Functional Decline and Cachexia to Inform more Holistic Therapies for Incurable Cancers.
Willbanks, A., Seals, M., Roy, I., Karmali, R.> ;Cancers. 2024 Jan 14
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
Gerson, J., Handorf, E., Villa, D., Gerrie, A., Chapani, P., Li, S., Medeiros, L., Wang, M., Cohen, J., Churnetski, M., Hill, B., Sawalha, Y., Hernandez-Ilizaliturri, ...> ;Blood Advances. 2023 Dec 26
4 citations
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
Zayac, A., Landsburg, D., Hughes, M., Bock, A., Nowakowski, G., Ayers, E., Girton, M., Hu, M., Beckman, A., Li, S., Medeiros, L., Chang, J., Stepanovic, A., Kurt, H., ...> ;Blood Advances. 2023 Nov 14
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
Narendranath Epperla, Lei Feng, Nirav N Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M Stephens, Catherine J Lee, Thomas Ollila, Geoffrey Shouse, Alexey V Danilov, Ke...> ;Journal of Hematology & Oncology. 2023 Nov 9
Prognostic significance of copy number gains ofdetected by fluorescencehybridization in large B-cell lymphoma.
Taylor Zak, Lucas Santana-Santos, Juehua Gao, Amir Behdad, Barina Aqil, Kristy Wolniak, Xinyan Lu, Peng Ji, Qing Chen, Yi-Hua Chen, Reem Karmali, Madina Sukhanova> ;Leukemia & Lymphoma. 2024 Jan 1
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study.
Kaitlin Annunzio, Natalie S Grover, Rina Li Welkie, Pallawi Torka, Marcus P Watkins, Andrea Anampa-Guzmán, Montreh Tavakkoli, Timothy S Oh, Heather Reves, Daniel Jones...> ;Blood Advances. 2023 Nov 28
2 citations
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.
Reem Karmali, Jeremy S Abramson, Shuo Ma, Juehua Gao, Adam M Petrich, Deborah M Stephens, Jeffrey Barnes, Jane N Winter, Jason Kaplan, Ephraim Hochberg, Tak Takvorian,...> ;Blood Advances. 2023 Dec 12
1 citations
Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T-cell therapy.
Nikita P Patel, Prarthana J Dalal, Zhiying Meng, Abigail S Baldridge, Gregory J Cascino, Ashwin Sunderraj, Arjun Sinha, Reem Karmali, Matthew J Feinstein, Nausheen Akhter> ;European Journal of Haematology. 2024 Jan 1
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Danielle S Wallace, Chris Rowland, Brian T Hill, Andrea M Baran, Carla Casulo, Patrick M Reagan, Allison Winter, Reem Karmali, Jane N Winter, Leo I Gordon, Andrew Bui,...> ;Leukemia & Lymphoma. 2023 Sep 1
4 citations
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.
Jia Ruan, Jasmine Zain, Brett Palmer, Borko Jovanovic, Xinlei Mi, Alok Swaroop, Jane N Winter, Leo I Gordon, Reem Karmali, Jonathan Moreira, Adam M Petrich, Barbara Pro> ;Blood Advances. 2023 Oct 10
3 citations
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.
Narendranath Epperla, Qiuhong Zhao, Reem Karmali, Pallawi Torka, Lauren Shea, Timothy S Oh, Andrea Anampa-Guzmán, Heather Reves, Montreh Tavakkoli, Irl Brian Greenwell...> ;Blood Advances. 2023 Sep 12
8 citations
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.
Major, A., Major, A., Kevin A David, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer, Mary-Kate Malecek, Jordan Carter, Adam Zayac, Myung Sun Kim, ...> ;American Journal of Hematology. 2023 Jun 1
6 citations
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.
Narendranath Epperla, Rina Li Welkie, Pallawi Torka, Geoffrey Shouse, Reem Karmali, Lauren Shea, Andrea Anampa-Guzmán, Timothy S Oh, Heather Reaves, Montreh Tavakkoli,...> ;Journal of Hematology & Oncology. 2023 May 8
Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study.
Frederique St Pierre, Reem Karmali, Xinlei Mi, Jennifer Boyer, Mariana Nieves, Michael G Ison, Jane N Winter, Leo I Gordon, Shuo Ma, Peter G Doukas> ;The Oncologist. 2023 Oct 3
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma.
Reem Karmali, Frederique St-Pierre, Leo I Gordon> ;Future Oncology. 2023 Apr 1
2 citations
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort.
Agrawal, P., David, K., Chen, Z., Sundaram, S., Kim, S., Vaca, R., Lin, Y., Singer, S., Malecek, M., Carter, J., Zayac, A., Kim, M., Reddy, N., Ney, D., Habib, A., Str...> ;Leukemia & Lymphoma. 2023 May 1
5 citations
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G Karrison, Rachel Treitman, Manali K Kamdar, Bradley M Haverkos, James Godfrey, Melissa A Babcook, Timothy J V...> ;Blood Advances. 2023 Aug 22
The Minimally Invasive Approach to the Diagnosis of an Undifferentiated Atrial Mass: A Case Series and Review of the Literature.
Eric P Cantey, Bianca Lavelle, Akhil Narang, Reem Karmali, Nausheen Akhter, Daniel Schimmel> ;CASE. 2023 Apr 1
11 citations
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investiga...
Locke J Bryan, Carla Casulo, Pamela B Allen, Scott E Smith, Hatice Savas, Gary L Dillehay, Reem Karmali, Barbara Pro, Kaitlyn L Kane, Latifa A Bazzi, Joan S Chmiel, Br...> ;JAMA Oncology. 2023 May 1
Join now to see all

Abstracts/Posters

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Mul...
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects in an Immune Competent Lymphoma Model
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Bio-Inspired Functional Lipoprotein-like Nanoparticles (Flip-NPs) Cause Cholesterol Starvation and Ferroptosis in B-Cell Lymphomas: Studies in Cell Lines, Xenograft Mo...
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Ibrutinib maintenance following induction for untreated mantle cell lymphoma (MCL): Initial safety report.
2019 ASCO Annual Meeting - 6/1/2019
Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Inhibition of Pro-Survival Pathways in DLBCL Cells By Functional Lipoprotein-like Nanoparticles
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

$Confronting Knowledge Gaps Concerning Relapsed/Refractory Follicular Lymphoma$
Confronting Knowledge Gaps Concerning Relapsed/Refractory Follicular LymphomaJune 22nd, 2022
Dr. Karmali on Challenges in MCLJuly 10th, 2019
Emerging Data Help Fine-Tune Treatment Strategies in Hodgkin Lymphoma and Follicular LymphomaApril 10th, 2019
Join now to see all